Complications associated with hematopoietic stem cell transplantation are common and frequently involve the gastrointestinal tract and other abdominal organs. Imaging is often used to help to confirm or exclude a suspected complication and to facilitate management. In this article, we review the imaging findings of abdominal complications related to hematopoietic stem cell transplantation.
Hematopoietic stem cell transplantation (HSCT) is used to treat a variety of life-threatening malignant and nonmalignant hematologic conditions, such as leukaemia, lymphoma, and severe aplastic anemia. HSCT is associated with a high rate of complications and is usually reserved for patients for whom conventional therapy has failed. HSCT involves preparation of the patient with a conditioning regimen, followed by transfusion. Conditioning regimens involve total-body irradiation and/or high-dose chemotherapy to eradicate the original disease and suppress the recipient's immune system so that it will not reject the donor's stem cells. Conditioning results in an immune compromised host. Transfusion of stem cells is then performed to reestablish hematopoietic function and/or to exert graft-versus-tumour effect. Complications after HSCT are common and can involve virtually any organ. The gastrointestinal tract and abdominal organs are frequently involved. Knowledge of the range of imaging findings is helpful in the diagnosis of abdominal complications.
Abdominal Complications
Gastrointestinal Tract
Graft-versus-host disease
Graft-versus-host disease (GVHD) is an immunemediated reaction of the donor T lymphocytes (graft) to the recipient (host), which leads to epithelial damage of the recipient organs. GVHD is the primary cause for morbidity and mortality in patients with HSCT. Acute GVHD occurs within 100 days of HSCT. Both small and large bowel may be involved. Computed tomographic (CT) findings typically include diffuse, mild bowel-wall thickening; intense enhancement of the bowel mucosa; and dilatation of affected bowel (Figures 1 and 2 ). The degree of mucosal enhancement and bowel dilatation tends to be greater with acute GVHD compared with neutropenic enterocolitis or pseudomembranous colitis (PMC) [1] . Associated findings of acute GVHD may include engorgement of the adjacent vasa recta, perienteric stranding, and ascites. On histopathologic examination, the abnormally enhanced mucosal layer seen on CT corresponds to mucosal destruction and replacement with granulation tissue (Figure 3 ). Chronic GVHD occurs 100 days or more after HSCT and affects approximately 40%-80% of long-term survivors. Small and large bowel strictures are uncommon but may occur, which leads to intestinal obstruction.
PMC
PMC or Clostridium difficile colitis usually develops as a result of broad-spectrum antimicrobials or chemotherapy agents with antibacterial properties used during the conditioning phase. PMC is typically isolated to the colon and commonly involves the entire colon. Typical findings on CT include diffuse, marked colonic thickening that tends to be more pronounced compared with GVHD and other colitides [1] . The ''accordion sign,'' which represents oedematous haustral folds, is characteristic of PMC ( Figure 4 ). Associated findings may include ascites and mesenteric stranding.
Infective enterocolitis
Viral infections, for example, cytomegalovirus colitis, may occur in the early post-transplantation period (1-3 months). CT findings include marked bowel-wall thickening, which can involve the entire colon, although the cecum is the most common site. The imaging appearance may mimic PMC ( Figure 5 ).
Neutropenic enterocolitis (typhlitis)
Neutropenic enterocolitis, also known as typhlitis, is a potentially life-threatening intestinal inflammation that predominantly involves the cecum, ascending colon, and distal ileum but may involve any segment of small or large bowel [1] . Patients typically present with right lower quadrant pain, fever, and diarrhoea. The process begins with mucosal disruption, which leads to intramural infection and, in severe cases, may lead to colonic necrosis and perforation. The toxic effects of chemotherapeutic agents may also contribute to altered mucosal integrity [2] . The typical finding on CT is marked cecal-wall thickening. Stranding of the pericecal fat and ascites is present in approximately 50% of cases ( Figure 6 ) [1] . The presence of associated small bowel involvement helps to differentiate neutropenic enterocolitis from PMC.
Pneumatosis intestinalis
There is an increased incidence of pneumatosis after HSCT, and the etiology is multifactorial. The use of steroids and the presence of GVHD are potential factors (Figure 7 ) [3] . Chemo-and/or radiotherapy or infection can also cause intestinal mucosal damage, which, in turn, allows intestinal gas to track through the mucosal defects into the bowel wall ( Figure 8 ). Gas may escape the intestinal wall and can be seen in the retroperitoneum or peritoneal cavity. Pneumatosis intestinalis usually involves the ascending colon and is often detected incidentally. However, it can occur in conjunction with neutropenic enterocolitis or cytomegalovirus colitis.
Post-transplant lymphoproliferative disorder
Post-transplant lymphoproliferative disorder is a rare sequela of chronic immunosuppressive therapy induced by Epstein-Barr virus. Most cases of post-transplant lymphoproliferative disorder occur in the first posttransplant year and affect 0.5%-1.5% of patients. CT features are similar to those of non-Hodgkin lymphoma and include abdominal and/or pelvic lymphadenopathy, hepatosplenomegaly, ascites, mesenteric mass, and bowelwall thickening.
Hepatic Complications

Hepatic Veno-occlusive Disease
Hepatic veno-occlusive disease (VOD) is a complication of the conditioning regimen. It typically occurs in the first 3 weeks after HSCT and affects 10%-60% of patients [4. It is caused by sloughing of the sinusoidal epithelium of intrahepatic venules and can result in venous congestion, hepatic necrosis, and eventually fibrosis. Risk factors include unrelated donor, prior hepatocellular damage, and high-dose chemoradiation therapy and anti-GVHD agents [4] . Patients typically present with tender hepatomegaly, weight gain, and jaundice. Imaging findings include hepatomegaly, narrowing of hepatic veins similar to Budd-Chiari type syndrome, gallbladder-wall thickening, and ascites ( Figure 9 ). The mortality rates for those with mild, moderate, and severe VOD are 9%, 23%, and 98%, respectively [5] . 
Hepatic GVHD
After the skin, the liver is the most frequently involved organ in GVHD. Hepatic GVHD is characterized by damage of the bile duct epithelial cells and sloughing of epithelial cells into the bile duct lumens. Clinical manifestations are cholestatic jaundice, nausea, vomiting, and abdominal pain. Damage to hepatocytes can also occur, and the clinical picture may resemble hepatitis. Liver biopsy is required in most cases to differentiate between VOD and hepatic GVHD, although periportal oedema and ascites are probably more common in VOD, whereas the presence of small bowel wall thickening favors the diagnosis of hepatic GVHD [4] .
Visceral Infection
Hepatic, splenic, and renal infections can occur, most commonly in the form of microabscesses caused by fungal infections. The typical hepatic and splenic appearances on CT are multiple, small, hypoattenuating ''target'' lesions with peripheral enhancement. Larger fungal abscesses are uncommon ( Figure 10 ).
Genitourinary Tract
Genitalia
Approximately 25% of long-term female survivors after allogeneic HSCT develop genital GVHD. Genital complications are usually associated with GVHD that involves other organs, with symptoms that range from vaginal and/or vulval irritation and ulceration to vaginal stenosis ( Figure 11 ) [6] .
Urinary Bladder
Hemorrhagic cystitis occurs in up to 76% patients after HSCT and is often due to cyclophosphamide treatment or may be related to GVHD [7] . Patients typically present with suprapubic pain and hematuria. Imaging shows bladder-wall thickening and sometimes intravesical material, which represents blood clots or sloughed mucosa ( Figure 12 ).
Other Complications
There is an increased risk of secondary malignancy, with an incidence rate of 4.2% at 10 years after HSCT [8] , particularly after total-body irradiation [9] . Some studies report a high frequency of late extramedullary relapses, with or without bone marrow involvement in patients with acute leukaemia after allogeneic bone marrow transplantation. Isolated extramedullary relapses that present as granulocytic sarcomas are rare, and the prognosis in these patients is generally poor (Figure 13 ) [10, 11] .
Conclusion
Abdominal complications after HSCT are common and potentially life threatening. Radiologists who serve this patient population should be familiar with the imaging findings to help confirm a suspected diagnosis or narrow the differential diagnosis. Figure 13 . A 37-year-old man with isolated extramedullary relapses. The patient underwent auto-and allogeneic bone marrow transplantation for diffuse large B-cell lymphoma 4 years earlier. Computed tomography, showing a large soft-tissue mass within the left renal sinus that extends into the anterior perinephric space. Open biopsy confirmed the diagnosis of granulocytic sarcoma.
